Fda guidance for post marketing study commitments professor pirouzi


Published on

FDA guidance for post marketing study commitments - Pharmaceuticals

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Fda guidance for post marketing study commitments professor pirouzi

  1. 1. FDA POST-MARKETING STUDY COMMITMENTS FOR SAFETY EVALUATION Professor Peivand Pirouzi 2010Food and Drug Administration Guidance Publications
  2. 2. Outline• Public health burden of serious adverse drug events• Reactions to drug safety systems• Pre-approval drug evaluation• Post-marketing safety evaluation• Potential solutions
  3. 3. Serious Adverse Drug Events The Magnitude• Approximately 100,000 drug-induced deaths/yr or the fifth leading cause of death• Serious adverse drug events account for an estimated 3-6% of all hospital admissions• Approximately 700,000 patients go to an Emergency Department for drug-induced, related adverse events• Enormous human and societal costs
  4. 4. Serious Adverse Drug Events Time Trends• From 1998 through 2005, 2.6-fold increase (from 35,000 to 90,000)• Reported events increased faster than number of prescriptions• Biotechnology products the worst• 300 drugs accounted for 87% of all reported events Moore et al., Arch Intern Med 2007;167:1752-9
  5. 5. Sources of Drug Safety InformationPre-approval Phase 2 and 3 trialsPost-approval Phase 4 trials MedWatch (N = 422,889 in 2004) Canada Vigilance International data
  6. 6. Asymmetry in the Evaluation• Approval is contingent on evidence of efficacy from well-designed and adequately powered clinical trials• Such trials are generally not designed to test specific hypotheses about safety• The pre-market safety evaluation is often exploratory
  7. 7. Pre-Approval PhasesPhase 1 Studies: Drug cautiously given to smallgroup of healthy volunteers (absorption,metabolism, excretion, early indications)Phase 2 Studies: Beneficial and adverse effects,and dosing in a few hundred patients with thetargeted conditionPhase 3 Trials: Comparative trials to determinebenefit vs. harm involving thousands of patients.Intended for regulatory approval and marketing
  8. 8. Pre-Approval Requirements• New drugs intended for long-term use in non-life threatening conditions:• A minimum of 1,500 patients exposed - 300 to 600 for 6 months - 100 for a year• Limits good evidence to: symptomatic improvement, efficacy and common side effects
  9. 9. Problems• Insufficient patient safety information for decision-making (approval• Limited safety data for populations most likely to be future users (elderly, those with co-morbidities)• Inadequate FDA review of design of studies for NDAs to achieve optimal detection of safety problems• Safety signals, even when recognized, often not actively pursued
  10. 10. Consequences• Unsafe drug approved for marketing• More than half have serious adverse drug events detected after approval• 10% have Black Box Warning added• Average number of patients exposed prior towithdrawal approximately 4 million• Example: Vioxx exposed to 20 million patients before wirthdrawal
  11. 11. Vioxx• A nonsteroidal anti-inflammatory drug (NSAID) that has now been withdrawn over safety concerns. It was marketed by Merck & Co. to treat osteoarthritis•• Approved as safe and effective by the Food and Drug Administration (FDA) on May 20, 1999• On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.• In the year before withdrawal, Merck had sales revenue of US$2.5 billion from Vioxx.• FDA analysts estimated that Vioxx caused between 88,000 and 139,000 heart attacks, 30 to 40 percent of which were probably fatal, in the five years the drug was on the market.
  12. 12. Solutions – Pre-Approval• More drug safety information - - Larger and longer trials - More relevant study populations• More thorough FDA review of protocol design• Proactive FDA pursuit of safety signals• Conditional approval, if safety problems suspected
  13. 13. Post-market Commitments• Today, 73% of new drugs have commitments agreed to by sponsors• Often multiple commitments by product• First commitment was for levodopa (1970) Therapeutic breakthrough for symptomatic relief; no cure, so concerns for long-term safety
  14. 14. Progress Report# of open commitments 1,281 pending 911 (71%) ongoing 173 (14%) delayed 39 (3%) submitted 157 (12%) Federal Register, April 24, 2008
  15. 15. Problems• Approval decisions rushed• Unmet commitments for safety trials• No penalties for failure to comply with post-approval study commitments• FDA lacks enforcement tools to leverage compliance• FDA’s historic post-marketing safety surveillance system is passive, insensitive and incomplete• High threshold of safety threat needed before FDA considers action (black box or withdrawal)
  16. 16. Solutions• Unmet safety commitments by manufacturers should be grounds for drug withdrawal• Authority to impose meaningful penalties for failing to conduct safety trials• Proactive post-marketing safety surveillance• Lower threshold for FDA actions
  17. 17. New Authority and Enforcement Tools• FDA gets the authority to require post marketing studies to identify or assess potential serious risks• FDA can also initiate timely label changes or new post marketing studies• FDA may also use Risk Evaluation and Mitigation Strategies to ensure benefits outweigh risks• Failure to comply may result in a determination of misbranding or escalating civil penalties Psaty & Korn, JAMA 2007;298:2185-7
  18. 18. Risk Management and Regulation Benefit Risk Balance Risk identification Risk Characterization Recognized benefit AdjustmentsRevise tools to improve Risk Minimization Tools Benefit/risk balance Risk reduction Risk communication Evaluation Testing the tools Reassess benefit/risk balance
  19. 19. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm
  20. 20. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm129511.pdf
  21. 21. Access to Data and Active Surveillance• FDA required to establish an active post marketing risk identification system• The system is to include 25 million patients by July 1, 2010, and 100 million by July 1, 2012• FDA to develop validated methods for the timely identification of adverse events and potential drug safety signals• Congress allocated $25 million per year ($65 million in 2012) Psaty & Korn, JAMA 2007;298:2185-7
  22. 22. Conclusions• Current drug safety systems need improvement - underway• Proactive safety evaluations needed• Retrospective - Database studies hold promise• Optimal compliance through understanding of strategies and tools